Onxeo S.A. buy melinda
Summary
This prediction ended on 23.12.10 with a price of €5.54. With a performance of -2.64%, the BUY prediction by melinda finished with a loss. melinda has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Onxeo S.A. | -4.140% | -4.140% | -69.878% | -85.777% |
iShares Core DAX® | -1.114% | 5.062% | 24.922% | 25.215% |
iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% | 44.324% |
iShares Nikkei 225® | 2.113% | 8.218% | 22.231% | 12.395% |
iShares S&P 500 | 2.038% | 7.448% | 30.358% | 43.899% |
According to melinda what are the pros and cons of Onxeo S.A. for the foreseeable future?
Pros
Cons
Comments by melinda for this prediction
In the thread Onxeo S.A. diskutieren
Pharma
BioAlliance, die bei Krebs und supportive care sehr gute Ergebnisse als kaufen spezialisiert
Stopped prediction by melinda for Onxeo S.A.
Onxeo S.A.
27.11.21
27.11.22
28.11.22
Onxeo S.A.
11.10.20
04.11.21
05.11.21
Onxeo S.A.
25.06.20
11.10.20
11.10.20
Onxeo S.A.
28.01.18
30.07.18
30.07.18
Onxeo S.A.
22.06.16
05.07.16
05.07.16
Onxeo S.A.
31.10.14
30.04.15
30.04.15